Abstract
Our findings suggest that targeting hypoxia stress and chemoresistance for therapeutic purposes and lincROR could promote the improvement of treatment responses in patients with DTX-resistant prostate cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have